Remission · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Dropout · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ not reported · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression rating scale score · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Remission · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depression rating scale scores ‐ not reported · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether riluzole changes acceptability: total dropouts compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes acceptability: total dropouts compared with placebo (very low certainty).
1 finding from 1 review
Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with midazolam (very low certainty).
1 finding from 1 review
Remission · adults (aged 18 years+) with depression in bipolar disorder
It is very uncertain whether ketamine changes efficacy: number of participants who achieve remission ‐ at 24 hours compared with midazolam (very low certainty).
1 finding from 1 review
Depressive symptoms · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18 years+) with depression in bipolar disorder
1 finding from 1 review
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
It is very uncertain whether ketamine changes efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (very low certainty).
1 finding from 1 review
OR 3.94 [1.54, 10.1]
Studies not reported
Very low
Withdrawals due to adverse events · adults with Major Depressive Disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: number of participants who respond to treatment ‐ at 24 hours · adults with Major Depressive Disorder
Esketamine may leads to higher efficacy: number of participants who respond to treatment ‐ at 24… compared with placebo (low certainty).
1 finding from 1 review
OR 2.11 [1.2, 3.68]
Studies not reported
Low
Remission · adults with Major Depressive Disorder
Esketamine probably leads to higher efficacy: number of participants who achieve remission ‐ at 24 hours… compared with placebo (moderate certainty).
1 finding from 1 review
OR 2.74 [1.71, 4.4]
Studies not reported
Moderate